Type I interferons in anticancer immunity

被引：1005

作者：

Zitvogel, Laurence ^{[1
,2
,3
,4
]}

Galluzzi, Lorenzo ^{[1
,5
,6
,7
,8
]}

Kepp, Oliver ^{[5
,6
,7
,8
]}

Smyth, Mark J. ^{[11
,12
]}

Kroemer, Guido ^{[5
,6
,7
,8
,9
,10
,13
]}

机构：

[1] Gustave Roussy Canc Campus, Villejuif, France

[2] INSERM, U1015, F-94800 Villejuif, France

[3] Univ Paris 11, Fac Med, F-94270 Le Kremlin Bicetre, France

[4] Ctr Clin Invest Biotherapies Canc CICBT 507, F-94800 Villejuif, France

[5] Ctr Rech Cordeliers, Equipe Labellisee Ligue Natl Canc 11, F-75006 Paris, France

[6] INSERM, U1138, F-75006 Paris, France

[7] Univ Paris 06, F-75006 Paris, France

[8] Univ Paris 06, F-75006 Paris, France

[9] Gustave Roussy Canc Campus, Metabol Platform, F-94800 Villejuif, France

[10] Gustave Roussy Canc Campus, Cell Biol Platform, F-94800 Villejuif, France

[11] Queensland Inst Med Res, Immunol Canc & Infect Lab, Berghofer Med Res Inst, Herston, Qld 4006, Australia

[12] Univ Queensland, Sch Med, Herston, Qld 4006, Australia

[13] Hop Europeen Georges Pompidou, F-75015 Paris, France

来源：

NATURE REVIEWS IMMUNOLOGY | 2015年 / 15卷 / 07期

基金：

英国医学研究理事会; 欧洲研究理事会;

关键词：

DENDRITIC CELL-RECEPTOR; IFN-ALPHA; T-CELLS; PEGYLATED INTERFERON-ALPHA-2B; MOLECULAR RESPONSE; ADAPTIVE IMMUNITY; ADJUVANT THERAPY; STEM-CELLS; CANCER; INNATE;

D O I：

10.1038/nri3845

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Type I interferons (IFNs) are known for their key role in antiviral immune responses. In this Review, we discuss accumulating evidence indicating that type I IFNs produced by malignant cells or tumour-infiltrating dendritic cells also control the autocrine or paracrine circuits that underlie cancer immunosurveillance. Many conventional chemotherapeutics, targeted anticancer agents, immunological adjuvants and oncolytic viruses are only fully efficient in the presence of intact type I IFN signalling. Moreover, the intratumoural expression levels of type I IFNs or of IFN-stimulated genes correlate with favourable disease outcome in several cohorts of patients with cancer. Finally, new anticancer immunotherapies are being developed that are based on recombinant type I IFNs, type I IFN-encoding vectors and type I IFN-expressing cells.

引用

页码：405 / 414

页数：10

共 124 条

[1] F-Actin Is an Evolutionarily Conserved Damage-Associated Molecular Pattern Recognized by DNGR-1, a Receptor for Dead Cells [J].

Ahrens, Susan ;

Zelenay, Santiago ;

Sancho, David ;

Hanc, Pavel ;

Kjaer, Svend ;

Feest, Christoph ;

Fletcher, Georgina ;

Durkin, Charlotte ;

Postigo, Antonio ;

Skehel, Mark ;

Batista, Facundo ;

Thompson, Barry ;

Way, Michael ;

Sousa, Caetano Reis e ;

Schulz, Oliver .

IMMUNITY, 2012, 36 (04) :635-645

[2] Toll-like receptor agonists in oncological indications [J].

Aranda, Fernando ;

Vacchelli, Erika ;

Obrist, Florine ;

Eggermont, Alexander ;

Galon, Jerome ;

Sautes-Fridman, Catherine ;

Cremer, Isabelle ;

ter Meulen, Jan Henrik ;

Zitvogel, Laurence ;

Kroemer, Guido ;

Galluzzi, Lorenzo .

ONCOIMMUNOLOGY, 2014, 3 (06)

[3] Immunostimulatory monoclonal antibodies in cancer therapy [J].

Aranda, Fernando ;

Vacchelli, Erika ;

Eggermont, Alexander ;

Galon, Jerome ;

Fridman, Wolf Herve ;

Zitvogel, Laurence ;

Kroemer, Guido ;

Galluzzi, Lorenzo .

ONCOIMMUNOLOGY, 2014, 3 (02)

[4] Production of type I interferons: plasmacytoid dendritic cells and beyond [J].

Asselin-Paturel, C ;

Trinchieri, G .

JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 202 (04) :461-465

[5] Interferon-α Suppresses cAMP to Disarm Human Regulatory T Cells [J].

Bacher, Nicole ;

Raker, Verena ;

Hofmann, Claudia ;

Graulich, Edith ;

Schwenk, Melanie ;

Baumgrass, Ria ;

Bopp, Tobias ;

Zechner, Ulrich ;

Merten, Luzie ;

Becker, Christian ;

Steinbrink, Kerstin .

CANCER RESEARCH, 2013, 73 (18) :5647-5656

[6] The antitumor effects of interferon-alpha are maintained in mice challenged with a STAT1-deficient murine melanoma cell line [J].

Badgwell, B ;

Lesinski, GB ;

Magro, C ;

Abood, G ;

Skaf, A ;

Carson, W .

JOURNAL OF SURGICAL RESEARCH, 2004, 116 (01) :129-136

[7] Immune Cell-Poor Melanomas Benefit from PD-1 Blockade after Targeted Type I IFN Activation [J].

Bald, Tobias ;

Landsberg, Jennifer ;

Lopez-Ramos, Dorys ;

Renn, Marcel ;

Glodde, Nicole ;

Jansen, Philipp ;

Gaffal, Evelyn ;

Steitz, Julia ;

Tolba, Rene ;

Kalinke, Ulrich ;

Limmer, Andreas ;

Jonsson, Goran ;

Hoelzel, Michael ;

Tueting, Thomas .

CANCER DISCOVERY, 2014, 4 (06) :674-687

[8] Bcr-abl signals to desensitize chronic myeloid leukemia cells to IFNα via accelerating the degradation of its receptor [J].

Bhattacharya, Sabyasachi ;

Zheng, Hui ;

Tzimas, Christos ;

Carroll, Martin ;

Baker, Darren P. ;

Fuchs, Serge Y. .

BLOOD, 2011, 118 (15) :4179-4187

[9] Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape [J].

Bidwell, Bradley N. ;

Slaney, Clare Y. ;

Withana, Nimali P. ;

Forster, Sam ;

Cao, Yuan ;

Loi, Sherene ;

Andrews, Daniel ;

Mikeska, Thomas ;

Mangan, Niamh E. ;

Samarajiwa, Shamith A. ;

de Weerd, Nicole A. ;

Gould, Jodee ;

Argani, Pedram ;

Moeller, Andreas ;

Smyth, Mark J. ;

Anderson, Robin L. ;

Hertzog, Paul J. ;

Parker, Belinda S. .

NATURE MEDICINE, 2012, 18 (08) :1224-1231

[10] Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell Immunity [J].

Broz, Miranda L. ;

Binnewies, Mikhail ;

Boldajipour, Bijan ;

Nelson, Amanda E. ;

Pollack, Joshua L. ;

Erle, David J. ;

Barczak, Andrea ;

Rosenblum, Michael D. ;

Daud, Adil ;

Barber, Diane L. ;

Amigorena, Sebastian ;

van't Veer, Laura J. ;

Sperling, Anne I. ;

Wolf, Denise M. ;

Krummel, Matthew F. .

CANCER CELL, 2014, 26 (05) :638-652

← 1 2 3 4 5 6 7 8 9 10 →